The results were heterogeneous: some trials, such as AMPLITUDE-O and SELECT, demonstrated significant reductions in HF-related endpoints, whereas others, like LEADER, showed only non-significant favourable trends
A small plastic or metal tube is inserted into the shoulder and connected with sterile plastic tubing to a special pump
This step is not optional
Wait for the second click, which confirms the full dose has been delivered
Recently, a phase 2b study for people with obesity has been completed and a press release revealed that danuglipron doses between 40 and 200 mg twice daily led up to 11.7% WL compared to 1.4% weight gain with placebo after 32 weeks of treatment [27]
It's usually funded by the supplement company if it's done at all, so that the opportunity for good evidence is almost nonexistent. This laissez-faire regulatory atmosphere has led to a wide variety of products that simply dont do what they say theyre going to door much of anything at all